The AstraZeneca share price steadies: is this FTSE 100 stock a good investment?

The AstraZeneca share price is showing resilience in the face of disappointing vaccine publicity. This FTSE 100 stock has a lot to like.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 pharmaceutical giant AstraZeneca (LSE:AZN) is showing resilience in the face of vaccine pushback. The company is behind one of the main vaccine rollouts, but 13 European countries have suspended the vaccine on concern it causes blood clots. However, the World Health Organisation (WHO) says there’s no evidence that the vaccine has any link to the clots. AstraZeneca’s share price seems to be holding steady despite the reports.

While the bad press is disappointing for the company, it has plenty of other projects in the pipeline to keep investors interested. Another Covid-19 therapy of note is its antibody treatment designed to boost the immune system of those unable to take the vaccine. The company has sold around $726m worth of this treatment to the US government year-to-date and analysts forecast it could bring in $3bn worth of revenue this year.

AstraZeneca share price fluctuations

The AstraZeneca share price has endured a rather disappointing eight months after the excitement of its vaccine potential sent it rocketing above £93 a share back in July. Today it’s hovering around £72.

For the last 12 months, its price-to-earnings ratio (P/E) is still high at 40. But its forward P/E is a more reasonable 19 and earnings per share are £1.75. It offers shareholders a 2.8% dividend yield.

Acquisitions extend its reach

The company has also been making moves in cancer treatments and rare diseases. Late last year it announced a major acquisition of US biotech company Alexion Pharmaceuticals for $39bn. The AstraZeneca share price took a hit on the news because Alexion was reportedly worth around $26bn. This meant investors thought AstraZeneca had overpaid.

However, many are starting to see the future benefits in owning Alexion, the purchase of which is set to complete in Q3. It should give AstraZeneca a much stronger presence in battling rare diseases. It should also help boost its offering of immunology drugs.

Alexion had a remarkable 2019, achieving six regulatory approvals, seven business development deals, and hiring 800 new employees. Its focus is on researching and treating rare and devastating diseases. This acquisition is not just strengthening AstraZeneca’s business, but it should help improve cash flow, allowing more money to be allocated to research and development (R&D). Analysts believe it may also lead to a stronger dividend payment.

In its bid to streamline the business, AstraZeneca also recently sold its stake in Moderna for over $1bn. This will help towards the Alexion acquisition.

Risks to the business

However, there are always risks worth being aware of and acquisitions can come with their own set of challenges. Legal risks abound, particularly when dealing with healthcare. Then there’s the fact AstraZeneca is paying over the odds. Will it generate enough cash and business opportunities to prove its worth? 

There’s also the risk of reputational damage if the vaccine (or other drug) doesn’t work out as planned. That’s the nature of pharmaceuticals and always a risk investors face.

With the impact of the Covid-19 pandemic not yet resolved, I believe much more focus and government money is likely to be willingly spent on healthcare R&D in the future. I like AstraZeneca and would happily add its shares to my long-term investment portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended Moderna Inc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »

Investing Articles

The latest growth forecasts suggest the Glencore share price will hit 555p!

Harvey Jones has been disappointed by the performance of the Glencore share price since he bought the commodity stock last…

Read more »

Dividend Shares

A closer look at the 11% dividend yield forecast for Phoenix Group shares

Phoenix Group shares have one of the highest dividend yields in the FTSE 100 index today. Could this be a…

Read more »

Investing Articles

If I’d put £25,000 into the FTSE 350 at the start of 2024, here’s how much I’d have today!

Many FTSE shares have rebounded this year as interest rates look set to keep heading lower and market appetite for…

Read more »

Investing Articles

Up 40%, but experts forecast the easyJet share price could soon hit 664p! Time to buy?

The easyJet share price has been flying lately and stock analysts are predicting more fun to come. But there's only…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Worried about tax raids? Here’s how I’m targeting a £44,526 passive income with shares

Investing in a Self-Invested Personal Pension (SIPP) or Individual Savings Account (ISA) can supercharge one's passive income, says Royston Wild.

Read more »